Simplex Trading
AXSM icon

Simplex Trading’s Axsome Therapeutics AXSM Stock Holding History

Simplex Trading’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.08M Sell
38,400
-3,100
-7% -$674K ﹤0.01% 951
2026
Q2 		$10.2M Buy
41,500
+37,700
+992% +$8.18M 0.01% 752
2026
Q1 		$642K Sell
3,800
-20,900
-85% -$3.61M ﹤0.01% 2978
2025
Q4 		$4.51M Buy
24,700
+2,600
+12% +$363K ﹤0.01% 1353
2025
Q3 		$2.68M Sell
22,100
-15,500
-41% -$1.75M ﹤0.01% 2023
2025
Q2 		$3.92M Buy
37,600
+16,500
+78% +$1.75M ﹤0.01% 1551
2025
Q1 		$2.46M Sell
21,100
-109,400
-84% -$12.5M ﹤0.01% 1854
2024
Q4 		$11M Buy
130,500
+31,400
+32% +$2.89M 0.01% 963
2024
Q3 		$8.91M Buy
99,100
+72,700
+275% +$6.35M 0.01% 1107
2024
Q2 		$2.12M Sell
26,400
-2,200
-8% -$163K ﹤0.01% 2143
2024
Q1 		$2.28M Buy
28,600
+11,300
+65% +$948K ﹤0.01% 2272
2023
Q4 		$1.38M Buy
17,300
+4,600
+36% +$308K ﹤0.01% 2706
2023
Q3 		$887K Sell
12,700
-39,100
-75% -$2.92M ﹤0.01% 2794
2023
Q2 		$3.72M Sell
51,800
-21,300
-29% -$1.57M ﹤0.01% 1516
2023
Q1 		$4.51M Sell
73,100
-24,000
-25% -$1.58M ﹤0.01% 1365
2022
Q4 		$7.49M Sell
97,100
-16,700
-15% -$998K 0.01% 991
2022
Q3 		$5.08M Sell
113,800
-93,900
-45% -$4.69M 0.01% 1198
2022
Q2 		$7.95M Buy
207,700
+148,200
+249% +$4.69M 0.01% 900
2022
Q1 		$2.46M Buy
59,500
+41,800
+236% +$1.3M ﹤0.01% 1891
2021
Q4 		$668K Buy
17,700
+16,200
+1,080% +$596K ﹤0.01% 3423
2021
Q3 		$102K Hold
1,500
– – ﹤0.01% 6592
2021
Q2 		$101K Buy
1,500
+1,470
+4,900% +$88.2K ﹤0.01% 6712
2021
Q1 		$169K Buy
+30
New +$2.11K ﹤0.01% 5005
2020
Q2 		– Sell
-727
Closed -$4.28M – 7585
2020
Q1 		$4.28M Sell
727
-275
-27% -$22.4K 0.01% 780
2019
Q4 		$10.4M Buy
1,002
+628
+168% +$25.4K 0.02% 451
2019
Q3 		$756K Buy
374
+17
+5% +$437 ﹤0.01% 2219
2019
Q2 		$919K Sell
357
-703
-66% -$14.1K ﹤0.01% 1980
2019
Q1 		$1.51M Buy
1,060
+1,056
+26,400% +$9.8K ﹤0.01% 1625
2018
Q4 		$1K Buy
+4
New +$13 ﹤0.01% 6704

Other funds holding AXSM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Simplex Trading's AXSM Position: Q3 2026 in Review

Simplex Trading reduced its Axsome Therapeutics (AXSM) stake by 15% in Q3 2026, selling an estimated $628K and leaving 16,755 shares worth $3.09M. The position accounts for ﹤0.01% of the portfolio, ranked #1574.

Simplex Trading first reported a position in AXSM in Q3 2018 and has held it in 30 quarters since. The position peaked at $4.81M in Q2 2026. 235 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Simplex Trading held 16,755 shares of Axsome Therapeutics worth $3.09M as of Q3 2026.
  • Simplex Trading sold 2,888 Axsome Therapeutics shares in Q3 2026, an estimated $628K.
  • Axsome Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q3 2026, its #1574 holding.
  • Simplex Trading first reported a position in Axsome Therapeutics in Q3 2018 and has held it in 30 quarters since.
  • Simplex Trading's Axsome Therapeutics position peaked at $4.81M in Q2 2026.
  • 235 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Simplex Trading's 13F filing for Q3 2026, filed 4 Nov 2026.